{"id":298,"date":"2020-06-22T06:55:25","date_gmt":"2020-06-22T06:55:25","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=298"},"modified":"2020-06-22T06:55:25","modified_gmt":"2020-06-22T06:55:25","slug":"22-june-2020-tocilizumab-improved-oxygenation-and-inflammatory-biomarkers","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/22-june-2020-tocilizumab-improved-oxygenation-and-inflammatory-biomarkers\/","title":{"rendered":"(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.chest.2020.06.006<\/p>\n<p class=\"\">Among 239 patients, median age was 64 years; 36% and 19% were Black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; p&lt;0.001), greater proportion requiring MV (44% vs 5%; p&lt;0.001) and longer median MV days (5.5 vs 1.0; p=0.003). Tocilizumab-treated patients (N=153, 64%) involved 90% of severe patients; 44% of non-severe patients received it for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission hsCRP levels (120 vs 71mg\/L; p&lt;0.001), received tocilizumab sooner (2 vs 3 days; p&lt;0.001), but survival was similar to non-severe patients (83% vs 91%; p=0.11). For tocilizumab-treated patients requiring MV, survival was 75% (95%CI=64%-89%). After tocilizumab, few adverse events occurred, oxygenation and inflammatory biomarkers (e.g., hsCRP, IL-6) improved; however, D-dimer and sIL2R levels increased significantly. Survival in Blacks and Hispanics, after controlling for age, was significantly higher than in whites (log-rank p=0.002).&nbsp; In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improve with higher than expected survival.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes https:\/\/doi.org\/10.1016\/j.chest.2020.06.006 Among 239 patients, median age was 64 years; 36% and 19% were Black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not.&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/22-june-2020-tocilizumab-improved-oxygenation-and-inflammatory-biomarkers\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(22 June 2020) Tocilizumab- improved oxygenation and inflammatory biomarkers&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/298"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=298"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/298\/revisions"}],"predecessor-version":[{"id":299,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/298\/revisions\/299"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}